SpaceX Joins Nasdaq 100; Crinetics Soars on $10B Vertex Buyout

SpaceX has been added to the Nasdaq 100 index, a move expected to provide considerable support to its stock due to the number of funds tracking the benchmark. Despite this inclusion, SpaceX's stock experienced a decline. At least six brokers, including Morgan Stanley and Goldman Sachs, have initiated coverage of SpaceX with buy-equivalent ratings, indicating positive analyst sentiment.

In other market movements, Crinetics Pharmaceuticals (CRNC) experienced a significant surge after Vertex Pharmaceuticals announced its agreement to acquire Crinetics for $10 billion in cash. This acquisition aims to expand Vertex's presence into the field of endocrinology. The deal represents a substantial valuation for Crinetics, with the company's stock soaring following the announcement.

Additionally, Fiserv (FISV) saw its stock climb following reports from The Wall Street Journal. The report indicated that major banks, including JPMorgan Chase, Bank of America, Wells Fargo, and PNC Financial Services Group, have engaged in preliminary discussions regarding a potential acquisition of a network owned by Fiserv. These discussions highlight potential consolidation and strategic moves within the financial technology sector.